Stockscreener 앱 받기
30.63
4.27%
-1.365
시장 영업 전:
21.50
-9.13
-29.81%
전일 마감가:
$32.00
열려 있는:
$32
하루 거래량:
3.48M
Relative Volume:
2.69
시가총액:
$1.95B
수익:
-
순이익/손실:
$-107.85M
주가수익비율:
-13.86
EPS:
-2.21
순현금흐름:
$-106.82M
1주 성능:
+53.69%
1개월 성능:
+19.98%
6개월 성능:
-36.33%
1년 성능:
-25.62%
1일 변동 폭
$30.37
$32.16
1주일 범위
$18.79
$33.00
52주 변동 폭
$18.53
$51.61
베라 테라 Stock (VERA) Company Profile
명칭
Vera Therapeutics Inc
전화
650-770-0077
주소
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
VERA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
30.63 | 1.27B | 0 | -107.85M | -106.82M | -2.21 |
|
ONC
Beone Medicines Ltd Adr
|
257.00 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.82 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.282 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
85.54 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
483.07 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
베라 테라 Stock (VERA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-05 | 재개 | H.C. Wainwright | Buy |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2025-01-28 | 개시 | Goldman | Buy |
| 2024-11-21 | 개시 | Wells Fargo | Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-01-25 | 개시 | Oppenheimer | Outperform |
| 2024-01-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-12-18 | 개시 | Raymond James | Outperform |
| 2023-11-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-16 | 개시 | Guggenheim | Buy |
| 2023-01-04 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-01-04 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-07-12 | 개시 | JP Morgan | Overweight |
| 2022-05-02 | 개시 | H.C. Wainwright | Buy |
| 2022-04-19 | 개시 | Wedbush | Outperform |
모두보기
베라 테라 주식(VERA)의 최신 뉴스
Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins - insights.citeline.com
Scotiabank Increases the Price Target for Vera Therapeutics by $10 - MSN
FY2025 EPS Forecast for Vera Therapeutics Reduced by Analyst - Defense World
(VERA) Trading Advice - news.stocktradersdaily.com
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Vera Therapeutics Enters $500M Credit Facility As It Nears FDA Filing For Kidney Disease Drug: Retail Sees Stock Touching $40 - MSN
Clinical-Stage Biotech Vera Therapeutics Joins Elite Goldman Sachs Healthcare Conference Lineup - Stock Titan
Latham & Watkins Advises Vera Therapeutics in US$500 Million Credit Facility With Oxford Finance - Latham & Watkins LLP
Vera Therapeutics Atacicept: Promising Step In IgAN, But Crowded Road Ahead (Rating Downgrade) - Seeking Alpha
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans - GlobeNewswire
Equities Analysts Set Expectations for VERA Q2 Earnings - Defense World
Vera Therapeutics (NASDAQ:VERA) Sees Large Volume Increase on Analyst Upgrade - Defense World
Vera Therapeutics eyes half billion dollars after kidney drug study - The Business Journals
Vera Therapeutics Enters $500M Credit Facility As It Nears FDA Filing For Kidney Disease Drug: Retail Sees Stock Touching $40 By Stocktwits - Investing.com India
Vera Therapeutics (VERA) Secures $500 Million Credit Facility - GuruFocus
Vera Therapeutics (VERA) Sees Price Target Boost Following Positive Trial Results | VERA Stock News - GuruFocus
Vera Therapeutics Secures $500M Loan Agreement - TipRanks
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 ... - Bluefield Daily Telegraph
Vera Therapeutics Lands Massive $500M Financing Deal as FDA Filing for Kidney Drug Approaches - Stock Titan
Two Sigma Investments LP Sells 7,102 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics (NASDAQ:VERA) Price Target Raised to $65.00 at Scotiabank - Defense World
Vera Therapeutics (NASDAQ:VERA) Given New $85.00 Price Target at HC Wainwright - Defense World
Why Vera Therapeutics, Inc. (VERA) Skyrocketed On Monday - Yahoo
These 10 Stocks Blew Past Expectations - Insider Monkey
Vera Therapeutics (NASDAQ:VERA) Shares Gap Up After Analyst Upgrade - Defense World
Vera Therapeutics: Primary endpoint was met in ORIGIN Phase 3 trial of atacicept - TipRanks
H.C. Wainwright ups Vera Therapeutics target on ‘home run’ data - TipRanks
Buy Rating for Vera Therapeutics: Promising Potential of Atacicept in IgA Nephropathy Treatment - TipRanks
Arthur He CFA Upgrades Vera Therapeutics on Promising Phase 3 Results for Atacicept in IgAN Treatment - TipRanks
Vera’s Atacicept Sets A New Efficacy Bar With Phase III Results In IgAN - insights.citeline.com
Vera Therapeutics (VERA) Surges 67.49% After Landmark Phase 3 Trial Results - Wealth Daily
Evercore ISI maintains outperform rating on Vera Therapeutics stock By Investing.com - Investing.com South Africa
Scotiabank Maintains Sector Outperform Rating for Vera Therapeutics (VERA) | VERA Stock News - GuruFocus
Vera rises after success in late-stage trial for IgA nephropathy treatment - Seeking Alpha
Wedbush Raises Price Target on Vera Therapeutics to $32 From $26, Maintains Neutral Rating - marketscreener.com
Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
Vera Therapeutics, Inc. Announces Atacicept Achieves 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy - marketscreener.com
Vera Therapeutics Reports Positive Phase 3 Results for Atacicept in IgA Nephropathy Treatment - geneonline.com
Scotiabank Increases Vera Therapeutics (VERA) Price Target to $65 | VERA Stock News - GuruFocus
Scotiabank Adjusts Price Target on Vera Therapeutics to $65 From $55, Maintains Outperform Rating - marketscreener.com
Vera Therapeutics Says Trial of Kidney Disease Drug Achieves Primary Endpoint; Shares Jump - marketscreener.com
JPMorgan reiterates Vera Therapeutics stock rating after study data By Investing.com - Investing.com South Africa
TD Cowen maintains buy rating for Vera Therapeutics stock - Investing.com
JPMorgan reiterates Vera Therapeutics stock rating after study data - Investing.com
Transcript : Vera Therapeutics, Inc.Special Call - marketscreener.com
VERA: HC Wainwright & Co. Raises Price Target for Vera Therapeutics | VERA Stock News - GuruFocus
Kidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data - Benzinga
Vera Therapeutics (VERA) Target Price Boosted Following Promising Study Results | VERA Stock News - GuruFocus
Pre-market Movers: LYRA, INM, OGEN, VERA... - RTTNews
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction In ORIGIN Phase 3 Trial In Adults With IgA Nephropathy - marketscreener.com
Vera Therapeutics Reports Atacicept Reduces Toxic Protein Levels in IgA Nephropathy Trial - geneonline.com
베라 테라 (VERA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
베라 테라 주식 (VERA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Fordyce Marshall | PRESIDENT AND CEO |
Feb 26 '25 |
Sale |
27.65 |
9,075 |
250,882 |
204,665 |
0.86%
1.24%
자본화:
|
볼륨(24시간):